{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:03:38Z","timestamp":1789844618640,"version":"4.0.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":341,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo, Co., Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials, and Methods<\/jats:title>\n                  <jats:p>Hepatic adverse reactions (ARs) were assessed by type and magnitude of liver test abnormalities, classified as (a) isolated aminotransferase elevations (alanine [ALT] or aspartate [AST], without significant alkaline phosphatase [ALP] or bilirubin elevations), or (b) mixed or cholestatic hepatotoxicity (increase in ALP with or without ALT\/AST and bilirubin elevations, based on adjudication). Median follow-up from initial pexidartinib treatment was 39 months (range, 32\u201382) in 140 patients with TGCTs across clinical studies NCT01004861, NCT02371369, NCT02734433, and NCT03291288.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 95% of patients with TGCTs (133\/140) treated with pexidartinib (median duration of exposure, 19 months [range, 1\u201376]), experienced a hepatic AR. A total of 128 patients (91%) had reversible, low-grade dose-dependent isolated AST\/ALT elevations without significant ALP elevations. Five patients (4%) experienced serious mixed or cholestatic injury. No case met Hy's law criteria. Onset of hepatic ARs was predominantly in the first 2 months. All five serious hepatic AR cases recovered 1\u20137 months following pexidartinib discontinuation. Five patients from the non-TGCT population (N =\u2009658) experienced serious hepatic ARs, two irreversible cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This pooled analysis provides information to help form the basis for the treating physician's risk assessment for patients with TCGTs, a locally aggressive but typically nonmetastatic tumor. In particular, long-term treatment with pexidartinib has a predictable effect on hepatic aminotransferases and unpredictable risk of serious cholestatic or mixed liver injury.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>This is the first long-term pooled analysis to report on the long-term hepatic safety of pexidartinib in patients with tenosynovial giant cell tumors associated with severe morbidity or functional limitations and not amenable to improvement with surgery. These findings extend beyond what has been previously published, describing the observed instances of hepatic toxicity following pexidartinib treatment across the clinical development program. This information is highly relevant for medical oncologists and orthopedic oncologists and provides guidance for its proper use for appropriate patients within the Pexidartinib Risk Evaluation and Mitigation Safety program.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13629","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T05:06:57Z","timestamp":1607490417000},"page":"e863-e873","source":"Crossref","is-referenced-by-count":57,"title":["Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors"],"prefix":"10.1093","volume":"26","author":[{"given":"James H.","family":"Lewis","sequence":"first","affiliation":[{"name":"Georgetown University Hospital, Washington, District of Columbia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Sande","sequence":"additional","affiliation":[{"name":"Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Healey","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Tap","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Lopez","family":"Pousa","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu I Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Druta","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo A.","family":"Baba","sequence":"additional","affiliation":[{"name":"University Hospital Essen, University of Duisburg-Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsook","family":"Choi","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale E.","family":"Shuster","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc, Basking Ridge, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[{"name":"University Hospital Essen, University of Duisburg-Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"2021122511543840800_onco13629-bib-0001","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: An international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122511543840800_onco13629-bib-0002","first-page":"100","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone","author":"Saint Aubain Somerhausen","year":"2013","edition":"4th ed"},{"key":"2021122511543840800_onco13629-bib-0003","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122511543840800_onco13629-bib-0004","article-title":"Limb amputation after multiple treatments of tenosynovial giant cell tumour: Series of 4 Dutch cases","volume":"2017","author":"Mastboom","year":"2017","journal-title":"Case Rep Orthop"},{"key":"2021122511543840800_onco13629-bib-0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1470-2045(19)30173-1","article-title":"Multidisciplinary care in tenosynovial giant cell tumours","volume":"20","author":"Tap","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122511543840800_onco13629-bib-0006","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122511543840800_onco13629-bib-0007","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-015-0385-x","article-title":"Current systemic treatment options for tenosynovial giant cell tumor\/pigmented villonodular synovitis: Targeting the CSF1\/CSF1R axis","volume":"17","author":"Brahmi","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"2021122511543840800_onco13629-bib-0008","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: A dose-escalation and dose-expansion phase 1 study","volume":"16","author":"Cassier","year":"2015","journal-title":"Lancet Oncol"},{"key":"2021122511543840800_onco13629-bib-0009","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: A multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122511543840800_onco13629-bib-0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5188-6","article-title":"Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: Initial experience of molecularly targeted therapy","volume":"18","author":"Nakayama","year":"2018","journal-title":"BMC Cancer"},{"key":"2021122511543840800_onco13629-bib-0011","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021122511543840800_onco13629-bib-0012","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","article-title":"Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis","volume":"23","author":"Ravi","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"2021122511543840800_onco13629-bib-0013","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CAD.0000000000000844","article-title":"Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour","volume":"31","author":"Rebuzzi","year":"2020","journal-title":"Anticancer Drugs"},{"key":"2021122511543840800_onco13629-bib-0014","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"2021122511543840800_onco13629-bib-0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/CCO.0b013e328354c16b","article-title":"Pigmented villonodular synovitis therapy with MSCF-1 inhibitors","volume":"24","author":"Temple","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2021122511543840800_onco13629-bib-0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced tenosynovial giant cell tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci Rep"},{"key":"2021122511543840800_onco13629-bib-0017","volume-title":"Prescribing information","author":"Turalio (pexidartinib) capsules, for oral use","year":"2020"},{"key":"2021122511543840800_onco13629-bib-0018","volume-title":"clinical practice guidelines in oncology: Soft tissue sarcoma\u2014version 5.2019","author":"NCCN","year":"2020"},{"key":"2021122511543840800_onco13629-bib-0019","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: Clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"2021122511543840800_onco13629-bib-0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2012.09.004","article-title":"Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis","volume":"39","author":"Teo","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2021122511543840800_onco13629-bib-0021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/17425255.2015.983075","article-title":"Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: A literature review","volume":"11","author":"Teo","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2021122511543840800_onco13629-bib-0022","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10637-019-00745-z","article-title":"A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors","volume":"38","author":"Lee","year":"2020","journal-title":"Invest New Drugs"},{"key":"2021122511543840800_onco13629-bib-0023","first-page":"2019","volume-title":"NDA 211810: Pexidartinib","author":"U.S. Food and Drug Administration. FDA Briefing Document. Oncologic Drugs Advisory Committee Meeting May 14","year":"2019"},{"key":"2021122511543840800_onco13629-bib-0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.gastro.2014.05.027","article-title":"Drug-induced liver injury: Morbidity, mortality, and Hy's law","volume":"147","author":"Regev","year":"2014","journal-title":"Gastroenterology"},{"key":"2021122511543840800_onco13629-bib-0025","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"2021122511543840800_onco13629-bib-0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-019-0112-z","article-title":"A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel","volume":"5","author":"Piawah","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"2021122511543840800_onco13629-bib-0027","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3899\/jrheum.141580","article-title":"Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy","volume":"42","author":"Genovese","year":"2015","journal-title":"J Rheumatol"},{"key":"2021122511543840800_onco13629-bib-0028","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1124\/jpet.118.254128","article-title":"Colony-stimulating factor-1 antibody lacnotuzumab in a phase 1 healthy volunteer study and mechanistic investigation of safety outcomes","volume":"369","author":"Pognan","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122511543840800_onco13629-bib-0029","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"2021122511543840800_onco13629-bib-0030","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"2021122511543840800_onco13629-bib-0031","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cgh.2014.02.011","article-title":"Drug-induced liver injury, dosage, and drug disposition: Is idiosyncrasy really unpredictable?","volume":"12","author":"Lewis","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122511543840800_onco13629-bib-0032","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2021122511543840800_onco13629-bib-0033","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.cgh.2015.06.017","article-title":"The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond","volume":"13","author":"Lewis","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122511543840800_onco13629-bib-0034","article-title":"Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: A disproportionality analysis of FDA adverse event reporting system","volume":"10","author":"Huang","year":"2020","journal-title":"Sci Rep"},{"key":"2021122511543840800_onco13629-bib-0035","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"2021122511543840800_onco13629-bib-0036","volume-title":"Clinical and research information on drug-induced liver injury","author":"LiverTox","year":"2012"},{"key":"2021122511543840800_onco13629-bib-0037","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4891-7","article-title":"Risk factors for erlotinib-induced hepatotoxicity: A retrospective follow-up study","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Cancer"},{"key":"2021122511543840800_onco13629-bib-0038","first-page":"89","article-title":"Vanishing bile duct disorders","volume":"10","author":"Desmet","year":"1992","journal-title":"Prog Liver Dis"},{"key":"2021122511543840800_onco13629-bib-0039","first-page":"87","article-title":"Histopathology of vanishing bile duct diseases","volume":"2","author":"Desmet","year":"1998","journal-title":"Adv Clin Path"},{"key":"2021122511543840800_onco13629-bib-0040","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbadis.2017.08.033","article-title":"Drug-induced bile duct injury","volume":"1864","author":"Visentin","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/5\/e863\/41923422\/oncolo_26_5_e863.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/5\/e863\/41923422\/oncolo_26_5_e863.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:56:48Z","timestamp":1640433408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/5\/e863\/6445662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,24]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,12,24]]},"published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13629","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,12,24]]}}}